Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis advanced non-small cell lung cancer patients – in the context of actual using of TKIs for NSCLC October 29, 2021October 27, 2021 by admin Alexandru Calin Grigorescu
